2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2017/050323, filed Sep 6, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,946,033 | 2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment In force · Medium confidence | Atea Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 11,975,016 | 2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment In force · Low confidence | Atea Pharmaceuticals, Inc. | In force | Low confidence | ||
| Application 16/821,850 | 2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment Abandoned Abandoned Nov 24, 2021 | Atea Pharmaceuticals, Inc. | Abandoned | Abandoned Nov 24, 2021 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Atea Pharmaceuticals, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.